AP NEWS

Acceleron to Participate in Two Upcoming Healthcare Investor Conferences

November 26, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 26, 2018--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences.

Conference Details :

Event: 30 th Annual Piper Jaffray Healthcare Conference Date/Time: Tuesday, November 27, 2018 at 9:00 a.m. EST Location: New York, NY

Event: 2018 Citi Global Healthcare Conference Date: Thursday, December 6, 2018 Location: New York, NY

A live webcast of the fireside chat at the Piper Jaffray Conference may be accessed on the Investors/Media page of the Company’s website at www.acceleronpharma.com. A replay of each webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company’s leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body’s ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.

For more information, please visit  www.acceleronpharma.com. Follow Acceleron on Social Media:  @AcceleronPharma and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181126005149/en/

CONTACT: Acceleron Pharma Inc.

Todd James, IRC, 617-649-9393

Vice President, Investor Relations and Corporate Communications

or

Candice Ellis, 617-649-9226

Manager, Investor Relations and Corporate Communications

or

Media:

Matt Fearer, 617-301-9557

Director, Corporate Communications

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL PROFESSIONAL SERVICES BANKING FINANCE COMMUNICATIONS RESEARCH PUBLIC RELATIONS/INVESTOR RELATIONS OTHER SCIENCE SCIENCE

SOURCE: Acceleron Pharma

Copyright Business Wire 2018.

PUB: 11/26/2018 07:00 AM/DISC: 11/26/2018 07:01 AM

http://www.businesswire.com/news/home/20181126005149/en

AP RADIO
Update hourly